Clinical Trials Directory

Trials / Completed

CompletedNCT04107779

Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS

A Randomized, Open Label, Parallel Group Study in Adult Smokers to Evaluate Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to Using JUUL Electronic Nicotine Delivery Systems With Two Different Nicotine Concentrations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
279 (actual)
Sponsor
Juul Labs, Inc. · Industry
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

A Randomized, Open Label, Parallel Group Study in Adult Smokers to Evaluate Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to using JUUL Electronic Nicotine Delivery Systems With Two Different Nicotine Concentrations

Detailed description

Previous studies and data reported in the literature support that Electronic Nicotine Delivery Systems (ENDS) have less toxicant exposure. This study will serve as a clinical evaluation of exclusive-use of selected JUUL ENDS in 2 different nicotine concentrations (5%, 3%), with the purpose of gaining data to support the hypothesis that exclusive-use of JUUL ENDS over the course of 6 days will result in a significant reduction in toxicant exposure compared to combustible cigarettes. This will be a randomized, open label, parallel group study in adult smokers to be conducted at up to 5 sites in the United States. Changes in Biomarkers of Exposure (BoEs) from baseline when using four JUUL ENDS with 2 different nicotine concentrations (5%, 3%) relative to Usual Brand (UB) of combustible cigarettes and a study group abstaining from any tobacco/nicotine product use will be assessed in this study. JUUL ENDS will be used either exclusively or partially (dual-use), with subjects in the dual-use group using both JUUL 5% ENDS (choice of Virginia Tobacco (VT), Mint, Menthol or Mango flavors) and UB of combustible cigarettes.

Conditions

Interventions

TypeNameDescription
OTHERSwitch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDSJUUL 5%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDSJUUL 3%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 5% Mint ENDSJUUL 5%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 3% Mint ENDSJUUL 3%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 5% Menthol ENDSJUUL 5%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 3% Menthol ENDSJUUL 3%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 5% Mango ENDSJUUL 5%, ENDS for 6-days in confinement
OTHERSwitch from UB of Combustible Cigarette to JUUL 3% Mango ENDSJUUL 3%, ENDS for 6-days in confinement
OTHERSwitch to Dual-use of JUUL 5% and UB of Combustible CigaretteCombination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
OTHERTobacco/Nicotine AbstentionNo smoking for 6-days in confinement.
OTHERUsual Brand of cigarettesContinue smoking UB for 6-days in confinement.

Timeline

Start date
2019-09-17
Primary completion
2020-02-17
Completion
2020-06-24
First posted
2019-09-27
Last updated
2020-07-28

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04107779. Inclusion in this directory is not an endorsement.